drugset / Trial / NCT02602002

Experimental Medicine Study to Validate Pharmacodynamic Pain Assessments in Healthy Volunteers With an Opioid Analgesic (Remifentanil)

NCT02602002

Phase 1 Completed 20 enrolled GlaxoSmithKline
RandomizedCrossoverDouble-blind

Summary

This was a single centre, randomised, double blind, placebo controlled, two-way cross-over design study to assess the feasibility of pain PD tests and to determine the variability and effects of a known analgesic drug (the opioid remifentanil) in South Korean healthy volunteers.

Timeline

Start
2008-04
Primary completion
2008-06
Completion
2008-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Remifentanil Small molecule 0.1 ug/kg

Indications

No indication recorded.